Network Pharmacology and Experimental Validation Reveal the Effects of Chidamide Combined With Aspirin on Acute Myeloid Leukemia-Myelodysplastic Syndrome Cells Through PI3K/AKT Pathway

Network Pharmacology and Experimental Validation Reveal the Effects of Chidamide Combined With Aspirin on Acute Myeloid Leukemia-Myelodysplastic Syndrome Cells Through PI3K/AKT Pathway

Chidamide (CDM), a novel histone deacetylase inhibitor, is currently used for patients with peripheral T-cell lymphoma. Aspirin (ASA), an anti-inflammatory drug, has been shown to exert anticancer activity. Herein, we investigated the effect of CDM combined with ASA on myelodysplastic syndromes-deri...

Full description

Bibliographic Details
Main Authors: Simin Liang, Xiaojia Zhou, Duo Cai, Fernando Rodrigues-Lima, Jianxiang Chi, Li Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-09-01
Series:Frontiers in Cell and Developmental Biology
Subjects:
chidamide
aspirin
network pharmacology
myelodysplastic syndromes
PI3K/Akt pathway
Online Access:https://www.frontiersin.org/articles/10.3389/fcell.2021.685954/full

Internet

https://www.frontiersin.org/articles/10.3389/fcell.2021.685954/full

Similar Items